ArticleHealth economics review2026
The cost-effectiveness of telestroke in the treatment of acute ischemic stroke in China.
Article in Health economics review, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundTelestroke improves access to stroke care in underserved areas but requires a high initial investment. Evidence on its cost-effectiveness is limited in developing countries. This study aims to evaluate the cost-effectiveness of treating acute ischemic stroke (AIS) patients with telestroke compared to non-telestroke in China.
methodsA Markov model is developed to assess the costs, quality-adjusted life-years (QALYs), and incremental cost-effectiveness ratio (ICER) of telestroke compared with non-telestroke over a lifetime horizon. The model incorporates four treatment pathways (intravenous thrombolysis (IVT), endovascular therapy (EVT), bridging therapy, and conservative treatment) and symptomatic intracerebral hemorrhage (sICH). Health states are divided into independent (modified Rankin Scale(mRS) 0–2), dependent (mRS 3–5), or deceased (mRS 6). The model cycle length is 1 year. Both costs and QALYs are discounted at 3% annually. The willingness-to-pay (WTP) threshold is set at 3 × gross domestic product per capita (268,074 Chinese Yuan (CNY) or 38,042 United States Dollar (USD) per QALY in 2023).
resultsCompared to non-telestroke, telestroke increases costs by 18,020 CNY and adds 0.1142 QALYs, resulting in an ICER of 157,763 CNY (22,388 USD) per QALY in lifetime horizon. One-way sensitivity analyses reveal that ICER is most sensitive to the probability of patients being independent (mRS 0–2) after EVT. Probabilistic sensitivity analysis shows that telestroke is cost-effective in 86.59% of the 10,000 simulations.
conclusionsTelestroke is cost-effective for AIS management in China, supporting its broader adoption.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.